CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-23

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors

NCT04883970

Gastrointestinal Cancer

ACTIVE_NOT_RECRUITING NA

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

NCT05803746

Lung Cancer Colorectal Cancer

UNKNOWN NA

68Ga-PMD22 PET/CT Examination Targeting CLDN18.2

NCT05937919

Gastrointestinal Cancer

UNKNOWN EARLY_PHASE1

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

NCT05156515

Lung Cancer Melanoma PD-L1 +1 more

UNKNOWN NA

Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors

NCT07301814

Gastric Cancer Pancreatic Cancer Cholangiocarcinoma Cancer +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

68Ga-ACN376

Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET/CT scan.

Group Type EXPERIMENTAL

18F-FDG

Intervention Type DRUG

All study participants will undergo one 18F-FDG PET/CT scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-FDG

All study participants will undergo one 18F-FDG PET/CT scan.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Aged \>18 years old; ECOG 0 or 1;
* 2\. Patients with solid tumors;
* 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
* 4\. life expectancy \>=12 weeks.

Exclusion Criteria

* 1\. Significant hepatic or renal dysfunction;
* 2\. Is pregnant or ready to pregnant;
* 3\. Cannot keep their states for half an hour;
* 4\. Refusal to join the clinical study;
* 5\. Suffering from claustrophobia or other mental diseases;
* 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No